-

Consonance-HFW Acquisition Corp. Announces Pricing of Its Initial Public Offering

NEW YORK--(BUSINESS WIRE)--Consonance-HFW Acquisition Corp. (“Consonance-HFW”) announced today the pricing of its initial public offering of 8,000,000 units, at a price to the public of $10.00 per unit, for aggregate gross proceeds of $80,000,000. Each unit consists of one Class A ordinary share and one-third of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share. The units are expected to begin trading on the New York Stock Exchange on November 19, 2020 under the symbol “CHFW.U”. The offering is expected to close on November 23, 2020, subject to customary closing conditions.

Consonance-HFW is a newly incorporated blank check company, incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, which we refer to as our initial business combination. While Consonance-HFW may acquire a company in any industry, it expects that its focus will be on the healthcare industry, particularly the biotechnology sector, in developed countries including, but not limited to, the United States and countries in Europe.

J.P. Morgan Securities LLC is acting as the sole book-running manager for the offering. Consonance-HFW has granted the underwriter a 45-day option to purchase up to an additional 1,200,000 units at the initial offering price to cover over-allotments, if any.

The offering of these securities is being made only by means of a prospectus. Copies of the prospectus relating to this offering, when available, may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (866) 803-9204 or by email at prospectus-eq_fin@jpmchase.com.

A registration statement relating to the sale of these securities was filed with, and declared effective by, the Securities and Exchange Commission. Copies of the registration statement can be accessed through the Securities and Exchange Commission’s website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to Consonance-HFW’s offering and search for an initial business combination. No assurance can be given that the offering will be completed on the terms described, or at all. Forward-looking statements are subject to numerous risks and conditions, many of which are beyond the control of Consonance-HFW, including those set forth in the Risk Factors section of Consonance-HFW’s registration statement relating to the offering. Consonance-HFW undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contacts

Joshua House
Consonance-HFW Acquisition Corp.
CHFW-info@consonancelifesciences.com

Consonance-HFW Acquisition Corp.

NYSEAM:CHFW.U

Release Versions

Contacts

Joshua House
Consonance-HFW Acquisition Corp.
CHFW-info@consonancelifesciences.com

More News From Consonance-HFW Acquisition Corp.

Surrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue Regeneration

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Surrozen, Inc. (“Surrozen”), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced the completion of its business combination with Consonance-HFW Acquisition Corp. (“Consonance-HFW”), a special purpose acquisition company (“SPAC”) sponsored by entities affiliated with Consonance Capital Management. The resulting combined company will commence trading its shares on Nas...

New Surrozen to Trade on Nasdaq as “SRZN”

PRINCETON, N.J.--(BUSINESS WIRE)--Consonance-HFW Acquisition Corp. (NYSE American LLC: CHFW) (“CHFW”) today announced that, upon the Domestication and the consummation of its pending business combination (the “Business Combination”) with Surrozen, Inc. (“Surrozen”), New Surrozen Common Stock and New Surrozen Warrants (each as defined below) will be listed on The Nasdaq Global Select Market (“Nasdaq”). Prior to the consummation of the Business Combination, CHFW will domesticate as a Delaware cor...

Surrozen and Consonance-HFW Acquisition Corp. Announce Business Combination, Creating Publicly Listed Leader in Wnt Biology and Tissue Regeneration

PRINCETON, N.J.--(BUSINESS WIRE)--Surrozen, Inc. (“Surrozen”), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, and Consonance-HFW Acquisition Corp. (NYSE American LLC: CHFW.U) (“Consonance-HFW”), a special purpose acquisition company (“SPAC”) sponsored by entities affiliated with Consonance Capital Management, today announced they have entered into a definitive business combination agreement. On the day of closing of the b...
Back to Newsroom